ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 164 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $255,000 | -24.8% | 5,000 | 0.0% | 0.01% | -38.5% |
| Q1 2017 | $339,000 | -75.9% | 5,000 | -75.0% | 0.01% | -80.9% |
| Q4 2016 | $1,406,000 | -7.8% | 20,000 | -7.0% | 0.07% | -27.7% |
| Q3 2016 | $1,525,000 | +42.5% | 21,500 | -1.7% | 0.09% | +13.3% |
| Q2 2016 | $1,070,000 | -32.4% | 21,870 | -12.5% | 0.08% | +20.3% |
| Q1 2016 | $1,583,000 | -5.9% | 25,000 | +66.7% | 0.07% | -40.5% |
| Q4 2015 | $1,683,000 | +16.5% | 15,000 | 0.0% | 0.12% | +81.2% |
| Q3 2015 | $1,445,000 | -90.2% | 15,000 | -89.5% | 0.06% | -89.0% |
| Q2 2015 | $14,686,000 | +64.9% | 143,432 | 0.0% | 0.58% | +46.8% |
| Q1 2015 | $8,906,000 | +43.5% | 143,432 | +1.4% | 0.40% | +84.6% |
| Q4 2014 | $6,206,000 | -22.5% | 141,432 | 0.0% | 0.21% | +9.2% |
| Q3 2014 | $8,005,000 | +125.2% | 141,432 | +78.6% | 0.20% | +154.5% |
| Q2 2014 | $3,555,000 | -3.5% | 79,200 | +5.1% | 0.08% | +4.1% |
| Q1 2014 | $3,684,000 | – | 75,350 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |